Gouty Arthritis in the Modern Era: Prevention, Management, and Future Directions

Gouty arthritis, or gout, is a chronic inflammatory condition characterized by the deposition of monosodium urate crystals in joints due to elevated serum uric acid levels (hyperuricemia). Once considered a ‘disease of kings’ gout is now recognized as a widespread metabolic disorder with increasing prevalence worldwide, particularly due to modern lifestyle factors such as poor diet, obesity, and sedentary habits. This review explores the current understanding of gouty arthritis in the context of its pathophysiology, clinical features, prevention strategies, and evolving therapeutic approaches. The review begins with a discussion of uric acid metabolism and the inflammatory cascade triggered by urate crystal deposition. Risk factors, including genetic predisposition, comorbidities such as hypertension and diabetes, and dietary contributors, are examined. Clinical diagnosis, based on symptomatology, laboratory findings, and imaging, is highlighted alongside the differentiation between acute attacks and chronic tophaceous gout. Current management includes both pharmacological agents, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), colchicine, corticosteroids, and uric acid-lowering drugs like allopurinol and febuxostat, and non-pharmacological measures like dietary modifications, weight control, and hydration. Preventive strategies are emphasized, especially for at-risk populations, with a focus on early intervention and patient education. Emerging therapies, including biologics targeting interleukin-1 (IL-1) and investigational agents in urate-lowering and anti-inflammatory categories, are discussed, along with the role of personalized medicine and genomic insights. An integrated approach combining lifestyle interventions, evidence-based pharmacotherapy, and future-oriented research is essential to improve patient outcomes and reduce the global burden of this painful yet manageable disease.